{"groups":[{"description":"Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","id":"FG000","title":"Pembrolizumab + Paclitaxel ± Bevacizumab"},{"description":"Participants receive placebo via IV infusion on Day 1 of each 6-week cycle for up to 18 cycles (approximately 2 years) PLUS paclitaxel 80 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an adverse event requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 every 3 weeks \\[Q3W\\]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.","id":"FG001","title":"Placebo + Paclitaxel ± Bevacizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"221"},{"groupId":"FG001","numSubjects":"240"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"95"},{"groupId":"FG001","numSubjects":"73"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"322"},{"groupId":"FG001","numSubjects":"321"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"320"},{"groupId":"FG001","numSubjects":"318"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"322"},{"groupId":"FG001","numSubjects":"321"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}